Ana Thereza Cavalcanti Rocha

Ana Thereza Cavalcanti Rocha

Auto-generated profile, based on publicly available information

Ana Thereza Cavalcanti Rocha

Universidade Federal da Bahia Escola Bahiana de Medicina e Saúde Pública, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Jornal Vascular Brasileiro
Verified
Journal Article
Open access
PDF file
ARAna Thereza Cavalcanti Rocha
Ana Thereza Cavalcanti Rocha
TPThiago Brito Pinheiro
Thiago Brito Pinheiro
PSPaulo Roberto Sampaio Peixoto de Souza
Paulo Roberto Sampaio Peixoto de Souza
Marcos Arêas MarquesMarcos Arêas Marques
Marcos Arêas Marques
Resumo Contexto Implementar um programa para profilaxia de tromboembolismo venoso (TEV) em hospitais é uma recomendação de diretrizes internacionais e da Agency for Healthcare Research and Quality para segurança dos pacientes. O Programa TEV Safety Zone (TEVSZ) é um modelo que sugere avaliação sistemática do risco de TEV incorporada às rotinas do hospital com participação institucional e multidisciplinar continuada. Objetivos Levantar dados de implementação de iniciativas para profilaxia em hospitais brasileiros que iniciaram o Programa TEVSZ. Métodos Envio de questionário por correio eletrônico aos responsáveis pelos programas TEVSZ em hospitais visitados até julho de 2016. Resultados Dos 132 convites enviados, foram obtidas 68 respostas, sendo 50 (73,5%) completas. Em 61,5% dos hospitais participantes havia entre 100 e 250 leitos, e 65,4% tinham mais de 20 leitos de terapia intensiva; 61,5% referiam ter acreditação hospitalar, 86,3% tinham comissão de profilaxia de TEV e 58% tinham prontuários eletrônicos. As avaliações de risco de TEV pela diretriz brasileira, escores de Pádua ou Caprini eram feitas no prontuário eletrônico em 56,9% e como passo obrigatório em 45,1% dos casos. Em apenas 25% dos hospitais, a reavaliação do risco de TEV era solicitada antes da alta, e foram citadas várias barreiras no processo de implementação do TEVSZ. Conclusões O estudo mostra um panorama da implementação do TEVSZ em hospitais brasileiros. As avaliações sistemáticas de risco ainda não ocorrem na maioria dos pacientes. O reconhecimento de diversas barreiras no processo pode levar a novas estratégias para a adequação da profilaxia e segurança dos pacientes hospitalizados.

1 January 2022 in Jornal Vascular Brasileiro
Verified
Journal Article
Open access
MCMaria Chiara Chindamo
Maria Chiara Chindamo
EPEdison Ferreira Paiva
Edison Ferreira Paiva
PJPlinio Resende Do Carmo Jr
Plinio Resende Do Carmo Jr
ARAna Thereza Cavalcanti Rocha
Ana Thereza Cavalcanti Rocha
Marcos Arêas MarquesMarcos Arêas Marques
Marcos Arêas Marques
Patients hospitalized for acute medical and surgical illnesses are at risk of developing venous thromboembolism (VTE) during hospitalization and after discharge. Extended pharmacological prophylaxis beyond the hospital stay is recommended for patients undergoing surgeries at high risk for VTE and for selected groups of hospitalized medical patients. This practice involves several challenges, from identification of at-risk populations eligible for extended prophylaxis to choice of the most appropriate anticoagulant and definition of the ideal duration of use. This review will present the main VTE risk assessment models for hospitalized medical and surgical patients, the current recommendations for use of extended prophylaxis, and its limitations and benefits.

1 January 2020 in Jornal Vascular Brasileiro
Verified
Journal Article
Open access
PDF file
Marcos Arêas MarquesMarcos Arêas Marques
Marcos Arêas Marques
CPCarmen Lucia Lascasas Porto
Carmen Lucia Lascasas Porto
AMAna Letícia de Matos Milhomens
Ana Letícia de Matos Milhomens
JVJuliana de Miranda Vieira
Juliana de Miranda Vieira
CGClaudia Carvalho Alcântara Gomes
Claudia Carvalho Alcântara Gomes
CMCíntia da Silva Miller
Cíntia da Silva Miller
Resumo A alopecia é uma complicação comum da terapia anticoagulante que pode ter repercussões psicológicas importantes nos pacientes, especialmente nos do sexo feminino, e interferir na decisão de extensão da anticoagulação. Esta revisão tem como objetivo descrever os mecanismos potencialmente envolvidos na gênese da alopecia durante a terapia anticoagulante, pois eles ainda não estão totalmente esclarecidos, e as terapias existentes, para a adoção das condutas mais adequadas.

14 April 2025 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
VAVeronica Moreira Amado1
Veronica Moreira Amado1
CFCaio Júlio César dos Santos Fernandes2
Caio Júlio César dos Santos Fernandes2
WSWilliam Salibe-Filho2
William Salibe-Filho2
MGMarcelo Basso Gazzana3
Marcelo Basso Gazzana3
ARAna Thereza Rocha4
Ana Thereza Rocha4
SMSuzana Minamoto
Suzana Minamoto
Venous thromboembolism (VTE) is the third most common acute cardiovascular syndrome after acute myocardial infarction and stroke. In recent years, there has been an increase in the incidence of VTE, related to population aging and common comorbidities in the elderly, including chronic cardiorespiratory disease and cancer. On the other hand, disease-related mortality, particularly for pulmonary embolism (PE), shows a decreasing trend, which can be explained by improvements in diagnostic imaging, advances in available therapies, and greater adherence to patient management protocols. The guidelines presented here provide recommendations for the pharmacological treatment of PE in Brazil, on the basis of scientific evidence and with a focus on common practical issues. Six Patient, Intervention, Comparison, and Outcome questions were developed by a group of experts on the topic. Systematic reviews of randomized clinical trials were conducted for each question, with meta-analyses being performed when possible. The level of evidence and strength of recommendation were defined in accordance with the Grading of Recommendations Assessment, Development, and Evaluation approach. With these guidelines, we expect to provide relevant, up-to-date information on the pharmacological treatment of PE.

1 January 2009 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
ARAna Thereza Rocha
Ana Thereza Rocha
EPEdison Ferreira de Paiva
Edison Ferreira de Paiva
WBWanderley Bernardo
Wanderley Bernardo

19 February 2025 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
RFRonney Argolo Ferreira1
Ronney Argolo Ferreira1
LZLian Zanatta1
Lian Zanatta1
JOJuliane Bispo de Oliveira1
Juliane Bispo de Oliveira1
JGJanaina Ibele Carvalho Gomes1
Janaina Ibele Carvalho Gomes1
LRLuiz Eduardo Ritt
Luiz Eduardo Ritt
2R2 Ana Thereza Cavalcanti Rocha1
2 Ana Thereza Cavalcanti Rocha1
Objectives: To evaluate the incidence of venous thromboembolism (VTE) in hospitalized patients with COVID-19 who underwent diagnostic tests for suspected VTE, and to correlate the IMPROVE-DD score with the incidence of VTE in this cohort. Methods: This retrospective study included consecutive patients with COVID-19 and suspected VTE, admitted between March 2020 and September 2021 at a private hospital in Salvador (BA), Brazil, who underwent lower or upper limb venous Doppler ultrasound or chest angiotomography. Descriptive analyses and comparisons using the chi-square test were performed to identify factors potentially associated with the risk of VTE. Results: A total of 517 patients were included, with an in-hospital VTE incidence of 18.6% (96 events). Risk factors significantly associated with VTE included obesity, ICU admission, central venous catheter use, longer hospital stays, greater lung tomographic involvement/severity, the need for mechanical ventilation, D-dimer levels at least twice the upper limit of normal (2xULN), and the IMPROVE-DD score. The mean IMPROVE-DD score among patients with VTE was 4.7 (±3) versus 3.3 (±2.4) in those without VTE (p < 0.0001). D-dimer 2xULN was sensitive in identifying 94% of the 96 patients with VTE (p < 0.0001). The in-hospital mortality rate was 14.1%, with higher rates observed in patients with VTE (24%) compared to those without VTE (11.9%) (p = 0.003). Conclusions: The incidence of VTE in hospitalized COVID-19 patients was high and correlated with increased mortality. The IMPROVE-DD score effectively identified patients at risk for in-hospital VTE, suggesting it could help to identify a high-risk subgroup that may benefit from extended thromboprophylaxis.